Comparison Between Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients With Acute Coronary Syndrome

• Status: Completed
• Trial end date: 2023-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will help us to compare atorvastatin and rosuvastatin in terms of their ability to reduce biomarkers of inflammation in patients of acute coronary syndrome

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rawalpindi Medical College
• Treatments: Atorvastatin; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

1. Patients with age 18 years and above, of both genders, diagnosed with acute coronary syndrome (as per operational definition) who were not taking statins previously.

2. Patients who sign written informed consent to participate in the study.

Exclusion Criteria:

• 1.Patients who are taking either statins and/or any other drug which lower serum lipid levels, patients with a history of statin hypersensitivity, patients in whom statins are contraindicated.

2.Patients who will be surgically managed will be also excluded. 3.if coronary revascularization will be planned or anticipated at the time of screening.

4.Pregnant or lactating women. 5.Patients having concomitant infections which cause the rise of inflammatory markers.